Skip to content
Screener

DBV Technologies DBVT Operating Cash Flow

Operating Cash Flow at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.99M-75.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$38.22M+33.7%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$14.81M+36.7%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$57.41M-30.5%
Alumis Inc. logo
Alumis Inc.ALMS
-$87.08M-8.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.3M+9.7%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNotesSix Months Ended June 30, 2026Six Months Ended June 30, 2025
(Decrease) increase in trade payables7(0.4)14.9
(Decrease) increase in other current and non-current liabilities(1.6)(1.5)
Change in operating lease liabilities and right of use assets6(0.1)0.3
Net cash flow used in operating activities(101.7)(53.6)
Cash flows used in investing activities :
Change in property, plant, and equipment(0.8)
Change in Other non-current assets5(0.1)(0.4)
Net cash flows used in investing activities(0.9)(0.4)

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's operating cash flow?
DBV Technologies (DBVT) reported operating cash flow of -$52.6M in Q2 2026.
How has DBV Technologies's operating cash flow changed year-over-year?
DBV Technologies's operating cash flow decreased by 55.2% year-over-year, from -$33.9M to -$52.6M.
What is the long-term trend for DBV Technologies's operating cash flow?
Over 4 years (2021 to 2025), DBV Technologies's operating cash flow has grown at a 2.9% compound annual growth rate (CAGR), from -$108.24M to -$121.18M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about DBV Technologies's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude